Diagnostik von Harnblasentumoren

Für die Prognose von Harnblasentumoren ist eine frühzeitige Diagnosestellung essenziell. Dieser Beitrag stellt die diagnostischen Algorithmen der Leitlinien von DGU und EAU vor und wirft einen Blick auf aktuelle Entwicklungen im Bereich der Diagnostik.

• Literatur

• 1 Krebs in Deutschland für 2013/2014. Robert Koch-Institut; 2017
• 2 Edwards TJ, Dickinson AJ, Natale S. et al. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int 2006; 97: 301-305 . discussion 5
• 3 S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1, AWMF-Registernummer: 032/038OL. Stand November 2016 www.awmf.org/uploads/tx_szleitlinien/032-038ol_l_S3_Harnblasenkarzinom_2016-12.pdf
• 4 Babjuk M, Böhle A, Burger M. et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017; 71: 447-461
• 5 Witjes JA, Lebret T, Compérat EM. et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017; 71: 462-475
• 6 Mowatt G, N'Dow J, Vale L. et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care 2011; 27: 3-10
• 7 Chou R, Selph S, Buckley DI. et al. Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis. J Urol 2017; 197: 548-558
• 8 Yafi FA, Brimo F, Steinberg J. et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 2015; 33: 66 e25–31
• 9 Raitanen MP, Aine R, Rintala E. et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002; 41: 284-289
• 10 Cambier S, Sylvester RJ, Collette L. et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016; 69: 60-69
• 11 Naselli A, Introini C, Timossi L. et al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. European urology 2012; 61 (05) 908-913
• 12 Bus MT, de Bruin DM, Faber DJ. et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol 2015; 29: 113-123
• 13 Bhat A, Ritch CR. Urinary biomarkers in bladder cancer: where do we stand?. Curr Opin Urol 2019; 29: 203-209
• 14 Heers H, Gut JM, Hegele A. et al. Non-invasive Detection of Bladder Tumors Through Volatile Organic Compounds: A Pilot Study with an Electronic Nose. Anticancer Res 2018; 38: 833-837